Drug Profile
Research programme: Respiratory syncytial virus monoclonal antibodies - X4 Pharmaceuticals
Alternative Names: ASN 500Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Adimab; Arsanis
- Developer Adimab
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections(Prevention) in USA (Parenteral)
- 13 Mar 2019 X4 Pharmaceuticals merged with Arsanis to form X4 Pharmaceuticals
- 31 Dec 2018 Arsanis plans phase I clinical trials of ASN 500 for Respiratory syncytial virus infections (Prevention) (Parenteral), in the first half of 2020